Jasper Therapeutics(US:JSPR) Newsfile·2025-11-13 01:55Core Viewpoint - Rosen Law Firm is reminding investors of Jasper Therapeutics, Inc. about the upcoming lead plaintiff deadline for a securities class action lawsuit, which is set for November 18, 2025 [1]. Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the November 18, 2025 deadline [3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 [4]. Group 3: Case Allegations - The lawsuit alleges that Jasper Therapeutics made false or misleading statements regarding its manufacturing controls and procedures, which could negatively impact the regulatory and commercial prospects of its products, particularly briquilimab [5]. - The claims suggest that the company's public statements were materially false and misleading, leading to investor damages when the true details became known [5].